Mirvetuximab soravtansine

Elahere

100 MG / 20 ML SolutionCanadaMarketedAuthorised 9 Jan 2026

In other countries

The same active substances on other registers, the same brand first.

ElahereBrazil · Abbvie Farmacêutica Ltda.Same brand
Elahere 5 MG/ML Concentrado Para Solucion Para PerfusionSpain · 105,50 mg · concentrado para solución para perfusión · Abbvie Deutschland Gmbh & Co. KgSame brand
ElahereEuropean Union · AbbVie Deutschland GmbH & Co. KGSame brand
ElahereCroatiaSame brand
ElahereItaly · Concentrato per soluzione per infusione · Abbvie Deutschland GMBH & Co. KGSame brand
ELAHERE 5 mg/ml concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · AbbVie Deutschland GmbH & Co. KGSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Mirvetuximab soravtansine

Elahere

100 MG / 20 ML SolutionCanadaMarketedAuthorised 9 Jan 2026

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Elahere Concentrate for Solution for Infusion 100MG/20ML

Singapore · 100mg/20mL · infusion, solution concentrate · Abbvie Pte. LTD.

ElahereUnited States · 100mg/20mL single-dose vial · injectable · Immunogen INC

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Mirvetuximab soravtansine
Strength: 100 MG / 20 ML
Dosage form: Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 9 Jan 2026
Registration: DIN 02560771
Marketing authorisation holder: Abbvie Corporation
ATC code: L01FX26
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION, SCHEDULE D